Almac doubles peptide capacity

Almac Group has announced the completion of two new purpose-built facilities at its headquarters in Craigavon, Northern Ireland. The total investment is about $400 million and is part of a global investment programme announced in June 2022.

One is a 2,600 m² GMP facility that more than doubles peptide API manufacturing capacity. This “will enhance synthesis, purification and isolation capabilities and meet anticipated demand for clinical development and commercial products”, the company said.

Almac has also completed a 3,000 m² high-volume facility for the manufacture and packaging of sachet drug products. The investment includes additional large-scale manufacturing suites, automated primary and secondary sachet packaging technologies, and also expands the company’s QC laboratory testing capacity.

Earlier investments in the ongoing programme have included: a centre of excellence for commercial drug product partnership; a CDx development, manufacturing and commercial centre; a drug substance GMP facility for clinical and commercial manufacturing; further expansion to clinical production and distribution capabilities in Souderton, Pennsylvania; and the launch of cryogenic and ultra-low service capabilities for clinical supply in Durham, North Carolina.